Meeting
2023 ASCO Annual Meeting
Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.
Authors
Chaosu Hu
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Chaosu Hu , Xiaomin Ou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT05628922
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS6112)
DOI
10.1200/JCO.2023.41.16_suppl.TPS6112
Abstract #
TPS6112
Poster Bd #
98b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety and efficacy of docetaxel combined with cisplatin as induction chemotherapy followed by cisplatin concurrent chemoradiotherapy plus gemcitabine as adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A prospective and multicenter phase II trial.
First Author: Zhi Hui Wang
Poster
2019 ASCO Annual Meeting
A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy.
First Author: Jingjing Miao
Poster
2013 ASCO Annual Meeting
Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC): Results after 06 years.
First Author: Esma Kerboua
Poster
2023 ASCO Annual Meeting
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
First Author: Chunmei Bai